Literature DB >> 34674567

Latency-associated Peptide Degradation Fragments Produced in Stellate Cells and Phagocytosed by Macrophages in Bile Duct-ligated Mouse Liver.

Ikuyo Inoue1, Xian-Yang Qin1, Takahiro Masaki2, Yoshihiro Mezaki2, Tomokazu Matsuura1,2, Soichi Kojima1, Yutaka Furutani1.   

Abstract

Transforming growth factor-β (TGF-β) activation is involved in various pathogeneses, such as fibrosis and malignancy. We previously showed that TGF-β was activated by serine protease plasma kallikrein-dependent digestion of latency-associated peptides (LAPs) and developed a method to detect LAP degradation products (LAP-DPs) in the liver and blood using specific monoclonal antibodies. Clinical studies have revealed that blood LAP-DPs are formed in the early stages of liver fibrosis. This study aimed to identify the cell source of LAP-DP formation during liver fibrosis. The N-terminals of LAP-DPs ending at residue Arg58 (R58) were stained in liver sections of a bile duct-ligated liver fibrosis model at 3 and 13 days. R58 LAP-DPs were detected in quiescent hepatic stellate cells at day 3 and in macrophages on day 13 after ligation of the bile duct. We then performed a detailed analysis of the axial localization of R58 signals in a single macrophage, visualized the cell membrane with the anti-CLEC4F antibody, and found R58 LAP-DPs surrounded by the membrane in phagocytosed debris that appeared to be dead cells. These findings suggest that in the early stages of liver fibrosis, TGF-β is activated on the membrane of stellate cells, and then the cells are phagocytosed after cell death.

Entities:  

Keywords:  LAP; TGF-β; liver fibrosis; plasma kallikrein

Mesh:

Substances:

Year:  2021        PMID: 34674567      PMCID: PMC8554581          DOI: 10.1369/00221554211053665

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  15 in total

Review 1.  Hepatic stellate cells and liver fibrosis.

Authors:  Juan E Puche; Yedidya Saiman; Scott L Friedman
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

2.  Latent TGF-β structure and activation.

Authors:  Minlong Shi; Jianghai Zhu; Rui Wang; Xing Chen; Lizhi Mi; Thomas Walz; Timothy A Springer
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

3.  Plasma Kallikrein-Dependent Transforming Growth Factor-β Activation in Patients With Chronic Pancreatitis and Pancreatic Cancer.

Authors:  Ryutaro Teraoka; Mitsuko Hara; Kazuhiro Kikuta; Yoshiki Hirooka; Yutaka Furutani; Tooru Shimosegawa; Atsushi Masamune; Soichi Kojima
Journal:  Pancreas       Date:  2017-03       Impact factor: 3.327

4.  Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β.

Authors:  Melody G Campbell; Anthony Cormier; Saburo Ito; Robert I Seed; Andrew J Bondesson; Jianlong Lou; James D Marks; Jody L Baron; Yifan Cheng; Stephen L Nishimura
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

5.  Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.

Authors:  Kuniha Konuma; Michiko Itoh; Takayoshi Suganami; Sayaka Kanai; Nobutaka Nakagawa; Takeru Sakai; Hiroyuki Kawano; Mitsuko Hara; Soichi Kojima; Yuichi Izumi; Yoshihiro Ogawa
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

6.  L(59) TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice.

Authors:  Mitsuko Hara; Ikuyo Inoue; Yuta Yamazaki; Akiko Kirita; Tomokazu Matsuura; Scott L Friedman; Daniel B Rifkin; Soichi Kojima
Journal:  Fibrogenesis Tissue Repair       Date:  2015-09-15

7.  Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.

Authors:  Rie Norita; Yasuhiro Suzuki; Yutaka Furutani; Kazuki Takahashi; Yasuhiro Yoshimatsu; Katarzyna A Podyma-Inoue; Tetsuro Watabe; Yasufumi Sato
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

8.  Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease.

Authors:  Hiroshi Yokoyama; Takahiro Masaki; Ikuyo Inoue; Mariko Nakamura; Yoshihiro Mezaki; Chisato Saeki; Tsunekazu Oikawa; Masayuki Saruta; Hiroyuki Takahashi; Masahiro Ikegami; Hiroshi Hano; Kenichi Ikejima; Soichi Kojima; Tomokazu Matsuura
Journal:  Heliyon       Date:  2019-02-16

9.  Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats.

Authors:  Monica Arias; Sibille Sauer-Lehnen; Jens Treptau; Nora Janoschek; Ingo Theuerkauf; Reinhard Buettner; Axel M Gressner; Ralf Weiskirchen
Journal:  BMC Gastroenterol       Date:  2003-10-18       Impact factor: 3.067

10.  LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis.

Authors:  Mitsuko Hara; Akiko Kirita; Wakako Kondo; Tomokazu Matsuura; Keisuke Nagatsuma; Naoshi Dohmae; Shinji Ogawa; Shinobu Imajoh-Ohmi; Scott L Friedman; Daniel B Rifkin; Soichi Kojima
Journal:  Springerplus       Date:  2014-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.